DEZHAN HEALTHCARE(SZ:000813)2023-04-27 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a growth of 15% compared to the previous year[13]. - The company's operating revenue for 2022 was ¥570,855,435.18, a decrease of 22.28% compared to ¥734,479,885.95 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥46,908,665.33, an improvement of 18.54% from -¥57,581,886.98 in 2021[19]. - The total revenue for 2022 was CNY 570.86 million, a decrease of 22.28% compared to the previous year[54]. - The pharmaceutical sector generated CNY 562.19 million in revenue, representing 98.48% of total revenue and a decline of 20.05% year-on-year[56]. - The company reported a significant increase in cash flow from operations, indicating potential for improved liquidity and operational efficiency moving forward[19]. - The company achieved a net increase in cash and cash equivalents of ¥1,122,599,535.77 in 2022, a significant improvement from a decrease of ¥349,738,061.95 in 2021, reflecting a 420.98% change[71]. - The company reported a total investment of 91,611.08 million CNY for various projects, achieving 100% of the planned investment[86]. User Growth and Market Expansion - User data showed a rise in active users, reaching 5 million, which is an increase of 20% year-on-year[13]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for 2023, indicating a projected growth of 25%[13]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in these regions[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[132]. - The company plans to enhance its digital platform, aiming for a 40% increase in online sales channels[132]. Research and Development - The company plans to invest 100 million RMB in R&D for new technologies over the next year[13]. - The company has established four specialized pharmaceutical research institutions with approximately 200 experienced R&D personnel, focusing on technological innovation and new drug development[43]. - The company has over 200 R&D personnel working on more than 20 projects, including several innovative drug candidates[50]. - The company is in the preclinical research phase for a new innovative drug targeting acute ischemic stroke, aiming for IND submission in approximately 1.5 years[67]. - The company has made progress in developing CBD-based treatments for rare diseases, with patent grants in major global markets[67]. - The company plans to accelerate the progress of R&D projects in 2023, with specific targets including entering clinical stages for the WYY project and ZT project, and achieving production approval for Trimetazidine Hydrochloride Tablets[100]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local health tech firm was completed, valued at 300 million RMB, to enhance technological capabilities[13]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[127]. - The company has established partnerships with two major distributors to enhance its supply chain efficiency[127]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency by reducing costs by 5% through process optimization initiatives[13]. - The company is actively pursuing cost reduction strategies, resulting in significant decreases in raw material costs[52]. - The company will implement cost reduction and efficiency enhancement strategies in 2023, aiming to improve capacity utilization and reduce unit costs through better supplier management and production technology innovation[101]. Risk Management - The management has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company faces risks from market and policy changes, particularly due to the ongoing reforms in the pharmaceutical industry and stricter regulations[103]. - The company will manage production cost risks by establishing long-term partnerships with quality suppliers and innovating production processes[104]. Governance and Compliance - The company maintains complete operational independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, and finance[112]. - The company has established a comprehensive financial management system, with independent accounting practices and tax obligations, ensuring no interference from the controlling shareholder[113]. - The company has a complete governance structure, with independent directors holding a majority in key committees, ensuring fair treatment of all shareholders[111]. - The company is committed to improving its governance structure by appointing qualified individuals to its board and management team[120]. Environmental Responsibility - The company has achieved compliance with national standards for pollution discharge in its production activities, with specific pollutant discharge limits outlined[172]. - The company has completed environmental impact report approvals for multiple projects, including the high Qing production base and Huan Tai medical beauty project[172]. - The company achieved a 100% compliance rate for wastewater discharge, meeting both Beijing and local sewage discharge standards[181]. - JiaLin Pharmaceutical invested approximately 2.01 million yuan in environmental governance and protection in 2022[180]. Shareholder Relations and Profit Distribution - No cash dividends will be distributed to shareholders for the fiscal year 2022, as the company focuses on reinvestment[4]. - The company reported a net profit attributable to shareholders of -46,908,665.33 CNY for 2022, with an initial undistributed profit of 3,894,471,040.61 CNY[151]. - The profit distribution plan for 2022 was deemed reasonable and compliant with relevant regulations, ensuring the protection of minority shareholders' interests[153]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,082, with 30 in the parent company and 1,052 in major subsidiaries[147]. - The company has implemented various training programs, including professional skills training and safety management, targeting different employee groups[150]. - The company emphasizes the importance of adjusting the shareholding structure before project initiation to prevent external shareholders from influencing future investments[146].